Article thumbnail

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model

By Salvador Arlandis-Guzman, Carlos Errando-Smet, Jeffrey Trocio, Daniel Arumi and Javier Rejas
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin
  2. (1997). A new questionnaire to assess the quality of life of urinary incontinent women.
  3. (2010). A proposed guideline for economic evaluation of health technologies. Gac Sanit
  4. (1998). A: Cost effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodynam
  5. (2009). A: Impact of fesoterodine on quality of life: pooled data from 2 randomized trials.
  6. (2003). A: Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia.
  7. (2006). A: The current and future burden and cost of overactive bladder in five European countries. http://Eur Urol
  8. (2003). A: The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology
  9. (2006). Abrams P: Men and women with overactive bladder symptoms report higher prevalence of depression and lower quality of life: results from the EPIC study. Neurourology & Urodynamics
  10. (2006). Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol
  11. (2001). AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.
  12. (2003). AJ: Prevalence and burden of overactive bladder in the United States. World J Urol
  13. (2006). Armstrong EP: Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy
  14. (2009). Base de datos de costes sanitarios.Edited by: Social,
  15. (2007). Bavendam T: Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder.
  16. (2004). Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther
  17. (2005). Castro-Diaz D: Persistence with antimuscarinic therapy in patients with overactive bladder.
  18. (2009). Catálogo de Especialidades Farmacéuticas. Consejo General de Colegios Oficiales de Farmacéuticos: Madrid:;
  19. (2000). Chokroverty S: Comorbidities associated with overactive bladder.
  20. (2007). Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol
  21. (2009). Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstet Gynecol Scand
  22. (2008). D: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol
  23. (2004). Defining overactive bladder: epidemiology and burden of disease. Urology
  24. (2006). Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
  25. (2006). Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin
  26. (2008). Estimation of a preference-based index from a condition-specific measure: the King’s Health Questionnaire. Med Decis Making
  27. (1989). Grimberg Guelar AM, Canosa Cucurull J, Saidler Mellibovsky L, Vivancos Lleida J: Aproximación a los costes de fracturas osteoporóticas de fémur en España. Med Clin (Barc)
  28. (2009). Grupo de Estudio Cooperativo EPICC: Prevalencia de incontinencia urinaria y vejiga hiperactiva en la población española: Resultados del estudio EPICC. Actas Urol Esp
  29. (2002). Health related consequences of overactive bladder.
  30. (2006). Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries.
  31. (2006). Impact of successful treatment of overactive bladder on health care resource use and productivity. Drug Benefit Trends
  32. (2010). Impacto de la morbilidad, uso de recursos y costes en el mantenimiento de la remisión de la depresión mayor en España: estudio longitudinal de ámbito poblacional. Gac Sanit
  33. (2010). Instituto Nacional de Estadística (INE):
  34. (2008). It’s just the worry about not being able to control it! A qualitative study of living with overactive bladder.
  35. (2002). JL: What is an efficient health technology in Spain? Gac Sanit
  36. (2004). KR: Does urinary incontinence affect middleaged and older women’s time use and activity patterns? Obstet Gynecol
  37. (2005). Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
  38. (2006). Major depression in female urinary incontinence. Psychosomatics
  39. (2010). Patient-reported reasons for discontinuing overactive bladder medication.
  40. (2005). Prevalencia de la vejiga hiperactiva en España: estudio poblacional. Arch Esp Urol
  41. (2006). Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct
  42. (2000). RG: Overactive bladder significantly affects quality of life.
  43. (2005). Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol
  44. (2005). Solifenacin Study Group: Long term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol
  45. (2010). Spain: Monthly, cumulated and TAM sales data of G4D4 (antimuscarinics). IMS Spanish sales data;
  46. (2005). TE: Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy
  47. (2010). The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
  48. (2004). The estimation of a preference-based measure of health from the SF-12. Med Care
  49. (2004). TL: The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health
  50. (2002). Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess
  51. (1999). Wein AJ: The overactive bladder and incontinence. Neurourol Urodyn